866-997-4948(US-Canada Toll Free)

Cancer Pain - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jun 2015

Category :

Cancer

No. of Pages : 137 Pages

Cancer Pain - Pipeline Review, H1 2015

Summary

Global Markets Directs, Cancer Pain - Pipeline Review, H1 2015, provides an overview of the Cancer Pains therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cancer Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cancer Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cancer Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cancer Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cancer Pain Overview 8
Therapeutics Development 9
Pipeline Products for Cancer Pain - Overview 9
Pipeline Products for Cancer Pain - Comparative Analysis 10
Cancer Pain - Therapeutics under Development by Companies 11
Cancer Pain - Therapeutics under Investigation by Universities/Institutes 15
Cancer Pain - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Cancer Pain - Products under Development by Companies 20
Cancer Pain - Products under Investigation by Universities/Institutes 23
Cancer Pain - Companies Involved in Therapeutics Development 24
Amgen Inc. 24
Amorsa Therapeutics Inc. 25
AngioChem Inc. 26
Aphios Corporation 27
AstraZeneca Plc 28
BCN Peptides, S.A. 29
Benitec Biopharma Limited 30
BioDelivery Sciences International, Inc. 31
ChironWells GmbH 32
Daiichi Sankyo Company, Limited 33
Grunenthal GmbH 34
GW Pharmaceuticals Plc 35
Immupharma Plc 36
IntelGenx Corp. 37
Kolon Life Science, Inc. 38
Nektar Therapeutics 39
Neurocentrx Pharma Ltd. 40
Nippon Kayaku Co., Ltd. 41
Northern Light Pharmaceuticals AB 42
Orion Oyj 43
Pain Therapeutics, Inc. 44
Pfizer Inc. 45
Pharmaleads 46
Recordati S.p.A. 47
Sorrento Therapeutics, Inc. 48
Virobay Inc. 49
Winston Pharmaceuticals, Inc. 50
Zynerba Pharmaceuticals, Inc. 51
Cancer Pain - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 55
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 62
AMS-410 ER12 - Drug Profile 62
ANG-2002 - Drug Profile 63
BBI-11008 - Drug Profile 64
calpastatin - Drug Profile 65
cebranopadol - Drug Profile 66
crotalphine - Drug Profile 68
DD-04107 - Drug Profile 69
dexmedetomidine hydrochloride - Drug Profile 70
dronabinol - Drug Profile 72
Drug for Cancer Neuropathic Pain - Drug Profile 73
fentanyl - Drug Profile 74
fentanyl citrate - Drug Profile 75
fentanyl citrate - Drug Profile 76
fulranumab - Drug Profile 77
HS-198 - Drug Profile 80
hydromorphone hydrochloride - Drug Profile 81
INT-0028 - Drug Profile 82
IPP-102199 - Drug Profile 83
ketamine hydrochloride ER - Drug Profile 84
KLS-2010 - Drug Profile 85
methadone hydrochloride - Drug Profile 86
nabiximols - Drug Profile 87
Nervarna - Drug Profile 90
NKTR-192 - Drug Profile 92
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - Drug Profile 93
PGN-202 - Drug Profile 94
PL-265 - Drug Profile 95
Q-201 - Drug Profile 96
QX-314 - Drug Profile 97
resiniferatoxin - Drug Profile 98
saracatinib difumarate - Drug Profile 99
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 101
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 102
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 103
Small Molecule to Antagonize Chemokine Receptor for Cancer Pain - Drug Profile 104
tanezumab - Drug Profile 105
VBY-825 - Drug Profile 107
zucapsaicin - Drug Profile 108
ZYN-001 - Drug Profile 110
Cancer Pain - Recent Pipeline Updates 111
Cancer Pain - Dormant Projects 122
Cancer Pain - Discontinued Products 126
Cancer Pain - Product Development Milestones 128
Featured News & Press Releases 128
Appendix 133
Methodology 133
Coverage 133
Secondary Research 133
Primary Research 133
Expert Panel Validation 133
Contact Us 133
Disclaimer 134

List of Tables
Number of Products under Development for Cancer Pain, H1 2015 12
Number of Products under Development for Cancer Pain - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Development by Companies, H1 2015 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Development, H1 2015 21
Comparative Analysis by Unknown Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2015 26
Cancer Pain - Pipeline by Amgen Inc., H1 2015 27
Cancer Pain - Pipeline by Amorsa Therapeutics Inc., H1 2015 28
Cancer Pain - Pipeline by AngioChem Inc., H1 2015 29
Cancer Pain - Pipeline by Aphios Corporation, H1 2015 30
Cancer Pain - Pipeline by AstraZeneca Plc, H1 2015 31
Cancer Pain - Pipeline by BCN Peptides, S.A., H1 2015 32
Cancer Pain - Pipeline by Benitec Biopharma Limited, H1 2015 33
Cancer Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2015 34
Cancer Pain - Pipeline by ChironWells GmbH, H1 2015 35
Cancer Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 36
Cancer Pain - Pipeline by Grunenthal GmbH, H1 2015 37
Cancer Pain - Pipeline by GW Pharmaceuticals Plc, H1 2015 38
Cancer Pain - Pipeline by Immupharma Plc, H1 2015 39
Cancer Pain - Pipeline by IntelGenx Corp., H1 2015 40
Cancer Pain - Pipeline by Kolon Life Science, Inc., H1 2015 41
Cancer Pain - Pipeline by Nektar Therapeutics, H1 2015 42
Cancer Pain - Pipeline by Neurocentrx Pharma Ltd., H1 2015 43
Cancer Pain - Pipeline by Nippon Kayaku Co., Ltd., H1 2015 44
Cancer Pain - Pipeline by Northern Light Pharmaceuticals AB, H1 2015 45
Cancer Pain - Pipeline by Orion Oyj, H1 2015 46
Cancer Pain - Pipeline by Pain Therapeutics, Inc., H1 2015 47
Cancer Pain - Pipeline by Pfizer Inc., H1 2015 48
Cancer Pain - Pipeline by Pharmaleads , H1 2015 49
Cancer Pain - Pipeline by Recordati S.p.A., H1 2015 50
Cancer Pain - Pipeline by Sorrento Therapeutics, Inc., H1 2015 51
Cancer Pain - Pipeline by Virobay Inc., H1 2015 52
Cancer Pain - Pipeline by Winston Pharmaceuticals, Inc., H1 2015 53
Cancer Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 54
Assessment by Monotherapy Products, H1 2015 55
Number of Products by Stage and Target, H1 2015 57
Number of Products by Stage and Mechanism of Action, H1 2015 59
Number of Products by Stage and Route of Administration, H1 2015 61
Number of Products by Stage and Molecule Type, H1 2015 64
Cancer Pain Therapeutics - Recent Pipeline Updates, H1 2015 114
Cancer Pain - Dormant Projects, H1 2015 125
Cancer Pain - Dormant Projects (Contd..1), H1 2015 126
Cancer Pain - Dormant Projects (Contd..2), H1 2015 127
Cancer Pain - Dormant Projects (Contd..3), H1 2015 128
Cancer Pain - Discontinued Products, H1 2015 129
Cancer Pain - Discontinued Products (Contd..1), H1 2015 130

List of Figures
Number of Products under Development for Cancer Pain, H1 2015 12
Number of Products under Development for Cancer Pain - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Products, H1 2015 21
Assessment by Monotherapy Products, H1 2015 55
Number of Products by Top 10 Targets, H1 2015 56
Number of Products by Stage and Top 10 Targets, H1 2015 56
Number of Products by Top 10 Mechanism of Actions, H1 2015 58
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 58
Number of Products by Top 10 Routes of Administration, H1 2015 60
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 60
Number of Products by Top 10 Molecule Types, H1 2015 62
Number of Products by Stage and Top 10 Molecule Types, H1 2015 63

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *